From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics Updated on Feb. 16th, 2025 – Since their discovery over thirty years ago, monoclonal antibodies (mAbs) based on Immunoglobulin G (IgG) have...
Challenging assumptions in antigen QC for antibody discovery success Not all projects go as planned, but breakthroughs often emerge from the most unexpected challenges. This case study explores how a technical obstacle during early QC could have derailed a VHH...
Synthetic Biology Technologies for Antibody Discovery Imagine bypassing the lengthy traditional immunization process and tapping into the antibody diversity equivalent of over a million llamas – right at your fingertips. At Isogenica, our libraries, built with...
Your Expert in Nanobodies Antibody Discovery Nanobody is widely used to describe single-domain antibodies, but VHH is the accurate term for the isolated variable domain found in camelid heavy-chain-only antibodies. Discover the Power of VHH's Nanobody or VHH...
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles In the fast-paced world of biotechnology, innovation often stems from taking smart, calculated risks. At Isogenica, we are used to running unusual antibody drug discovery...
Specific Antibodies to Difficult Targets: How to find the needles in the haystack Peptides, often small and unstructured, are some of the most difficult targets in antibody discovery. Here, we recount how we tweaked our approach to mining our vast VHH libraries to...
